REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Chemistry: Natural Resins Or Derivatives; Peptides Or Proteins; Lignins Or Reaction Products Thereof > Peptides Of 3 To 100 Amino Acid Residues Peptides Of 3 To 100 Amino Acid ResiduesPeptides Of 3 To 100 Amino Acid Residues patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/04/07 - 20070004904 - G-csf conjugates The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at ... 12/07/06 - 20060276622 - Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention relates to a process for the in vitro determination of antibodies, wherein the peptides ... 12/07/06 - 20060276621 - Glycosylated specificity exchangers The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. ... 11/30/06 - 20060270829 - G-csf conjugates The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at ... 11/23/06 - 20060264605 - Polypeptides having anti-hiv activity and compositions comprising same (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or ... 11/23/06 - 20060264604 - Anti-hbs monoclonal antibody An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: (i) a wild type HBsAg; (ii) at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and (iii) at least one mutant HBsAg selected from the ... 11/23/06 - 20060264603 - Kallikrein-binding kunitz domain proteins and analogues thereof This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. ... 10/12/06 - 20060229432 - Gp120 specific antigens and uses thereof wherein R1, R2A, R2B, R3, R4, W1, W2 and W3 are as defined herein; and additionally provides compositions thereof, and methods for their use in the treatment and/or prevention of HIV infection, and methods for inducing HIV-specific antibodies in a subject, comprising administering to a subject in need thereof, an ... 09/21/06 - 20060211846 - Zinc finger binding domains for nucleotide sequence ann Polypeptides that contain from 2 to 12 zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula (ANN)2-12 are provided. Polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides and polynucleotides are also provided. ... 09/14/06 - 20060205923 - Method and device for detecting feline immunodeficiency virus FIV gag polypeptides and a method and device for determining a feline immunodeficiency virus infection in an animal. The method includes contacting a biological sample from a felid with the FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. A device for detecting FIV antibodies ... 08/10/06 - 20060178501 - Pyy agonists and use thereof The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist. ... 08/03/06 - 20060173159 - Water-soluble thioester and selenoester compounds and methods for making and using the same Water-soluble thioester and selenoester compounds, their generators, as well as methods for making and using the same, are provided. The subject thioester and selenoester compounds are characterized by including an amino acid synthon having a C-terminal group bonded to a water-soluble polymer through a thioester or selenoester linkage. Solid phase ... 07/27/06 - 20060167220 - Methods and compositions for preparing peptides with excellent solubility characteristics in aqueous solution at physiological ph The formation of inactive, insoluble forms of peptide can be minimized or, alternatively, inactive, insoluble forms of peptide compounds, if present, can be converted into more physiologically active, soluble forms by dissolving peptide samples in aqueous base and then acidifying the aqueous mixture to precipitate the peptide in the presence ... 07/06/06 - 20060149032 - Recombinant hepatitis b surface antigen The present invention provides an improved rHBsAg that exhibits a higher antigenicity and immunogenicity than that previously known in the art. A method of making the improved rHBsAg is also provided. The improved HBsAg is used to provide vaccines with lower amounts of active ingredient, vaccines with higher immunogenicity and ... 06/22/06 - 20060135746 - Dual inhibitors of hiv-1 gp-120 interactions Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided. ... 06/15/06 - 20060128941 - Pokeweed antiviral protein polypeptides with antiviral activity A molecular model of pokeweed antiviral protein (PAP)-RNA interactions was used to rationally engineer FLP-102 (151AA152) and FLP-105 (191AG192) as nontoxic PAP proteins with potent anti-HIV activity. FLP-102 and FLP-105 have been produced in E. coli and tested both in vitro as well as in vivo. These proteins depurinate HIV-1 ... 06/08/06 - 20060122368 - Antigen delivery platform Polynucleotides encoding fusion proteins suitable as an antigen delivery platform are provided. Pharmaceutical compositions including the fusion proteins and methods for their use are also provided. ... 05/25/06 - 20060111551 - Peptide having htlv-1-specific ctl-inducing activity The present invention provides a peptide having HTLV-I-specific CTL-inducing activity that can induce cytotoxic T cells (CTL) having anti-tumor effect to human T cell leukemia virus-I (HTLV-I) tumor such as adult T-cell leukemia (ATL); a vaccine to induce immune response by using these; a diagnostic agent to examine immune function ... 02/16/06 - 20060036070 - Immunoglobulin a inducing protein and uses therefor The invention provides an isolated and purified nucleic acid molecule encoding mammalian immunoglobulin A inducing protein (IGIP), and methods of using the IGIP nucleic acid molecule and IGIP, e.g., to prepare antibodies. Also provided is an anti-IGIP antibody and uses therefor. ... 02/02/06 - 20060025565 - Isolation and use of motoneuronotrophic factor The present invention is directed to a novel purified polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO: 4, one of the member of the Motoneuronotrophic Factor family which has shown to have diagnostic and therapeutic applications in mammals. ... 01/26/06 - 20060020109 - Therapeutic peptides for demyelinating conditions The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition. ... 01/19/06 - 20060014926 - Human papillomavirus polypeptides and immunogenic compositions The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides ... 01/05/06 - 20060004184 - Method and device for detecting feline immunodeficiency virus A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected ... 12/01/05 - 20050267290 - Preparation of acid amides A method and apparatus suitable, inter alia, for producing carboxylic acid amides from carboxylic acid esters and amines in which a mixture of amide and alcohol is obtained, the mixture is maintained in a liquid state, and the alcohol which is released is progressively evaporated, after which the liquid carboxylic ... 11/17/05 - 20050256300 - Method for using a static electric field to induce crystallization and to control crystal form Applying a strong static DC electric field to supersaturated aqueous glycine solutions resulted in the nucleation of the γ polymorph attributed to the electric-field induced orientation of the highly polar glycine molecules in large preexisting solute clusters, helping them organize into a crystalline structure. A method to induce crystallization and ... 11/17/05 - 20050256299 - Antigenic polypeptides A method for the identification of antigenic polypeptides, typically opsonic antigens, expressed by pathogenic microbes; vaccines comprising said antigens; and therapeutic antibodies directed to said antigenic polypeptides. ... 10/27/05 - 20050240006 - Members of the fc receptor homolog gene family (fcrh1-3, 6), related reagents, and uses thereof The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory ... 08/04/05 - 20050171333 - Formulations and methods for denaturing proteins Reagents, methods and kits for denaturation of protein are provided. ... 07/21/05 - 20050159584 - Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas Process for the preparation of stable activated derivatives of carbamic acid, comprising at least one protected amino group and an activated carbamic acid function, from an amino acid derivative in which the amino group is protected. The process includes: a) a step of transformation of the —COOH group of the ... 06/30/05 - 20050143559 - Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition The present invention provides novel enzymes, tryparedoxins, their isolation from Crithidia fasciculata, a method for the production thereof in genetically transformed bacteria, and their use as molecular targets for the discovery of trypanocidal drugs ... ### FreshPatents.com Support |